Evidence map›Paper›PMID 35557495›Full record

ArticleAllergy, asthma & immunology research2022

Prescription Patterns of Oral Corticosteroids for Asthma Treatment and Related Asthma Phenotypes in University Hospitals in Korea.

Jae-Woo Kwon, Mi-Ae Kim, Da Woon Sim, Hwa Young Lee, Chin Kook Rhee, Min-Suk Yang, Ji-Su Shim, Min-Hye Kim, So Ri Kim, Chan Sun Park and 7 more

Abstract read
In one paragraph

Article in Allergy, asthma & immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Asthma and corticosteroids "Frontiers in allergy · 2026
    Review
  3. Review
  4. Observational
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jae-Woo KwonDivision of Allergy and Clinical Immunology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.ORCID https://orcid.org/0000-0003-1639-3606
Mi-Ae KimDepartment of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0003-1253-6075
Da Woon SimDivision of Allergy, Asthma, and Clinical Immunology, Department of Internal Medicine, Chonnam National University Medical School & Chonnam National University Hospital, Gwangju, Korea.ORCID https://orcid.org/0000-0002-9723-0720
Hwa Young LeeDivision of Allergy, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0002-1582-2256
Chin Kook RheeDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.ORCID https://orcid.org/0000-0003-4533-7937
Min-Suk YangDepartment of Internal Medicine, Seoul Metropolitan Government - Seoul National University Boramae Medical Center, Seoul, Korea.ORCID https://orcid.org/0000-0002-9861-0530
Ji-Su ShimDepartment of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8846-0364
Min-Hye KimDepartment of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-1775-3733
So Ri KimDivision of Respiratory Medicine and Allergy, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.ORCID https://orcid.org/0000-0002-6074-9158
Chan Sun ParkDepartment of Internal Medicine, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0003-0113-8354
Byung-Keun KimDivision of Pulmonology, Allergy and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-5147-6306
Sung-Yoon KangDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.ORCID https://orcid.org/0000-0001-5505-3028
Gil-Soon ChoiDepartment of Internal Medicine, Kosin University College of Medicine, Busan, Korea.ORCID https://orcid.org/0000-0003-3466-3294
Hyun LeeDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-1269-0913
An-Soo JangDepartment of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.ORCID https://orcid.org/0000-0001-5343-023X
Sang-Heon KimDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. sangheonkim@hanyang.ac.kr.ORCID https://orcid.org/0000-0001-8398-4444
Korean Academy of Asthma, Allergy, and Clinical Immunology (KAAACI), the Working Group on Severe Asthma

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOral corticosteroids (OCSs) are frequently prescribed for asthma management despite their adverse effects. An understanding of the pattern of OCS treatment is required to optimize asthma treatment and reduce OCS usage. This study evaluated the prescription patterns of OCSs in patients with asthma.

methodsThis is a retrospective multicenter observational study. We enrolled adult (≥18 years) patients with asthma who had been followed up by asthma specialists in 13 university hospitals for ≥3 years. Lung function tests, the number of asthma exacerbations, and prescription data, including the days of supply and OCS dosage, were collected. The clinical characteristics of OCS-dependent and exacerbation-prone asthmatic patients were evaluated.

resultsOf the 2,386 enrolled patients with asthma, 27.7% (n = 660) were OCS users (the median daily dose of OCS was 20 mg/day prednisolone equivalent to a median of 14 days/year). OCS users were more likely to be female, to be treated at higher asthma treatment steps, and to show poorer lung function and more frequent exacerbations in the previous year than non-OCS users. A total of 88.0% of OCS users were treated with OCS burst with a mean dose of 21.6 ± 10.2 mg per day prednisolone equivalent to 7.8 ± 3.2 days per event and 2.4 times per year. There were 2.1% (51/2,386) of patients with OCS-dependent asthma and 9.5% (227/2,386) with exacerbation-prone asthma. These asthma phenotypes were consistent over the 3 consecutive years in 47.1% of OCS-dependent asthmatic patients and 34.4% of exacerbation-prone asthmatic patients when assessed annually over the 3-year study period.

conclusionsWe used real-world data from university hospitals in Korea to describe the OCS prescription patterns and relievers in asthma. Novel strategies are required to reduce the burden of OCS use in patients with asthma.

Indexed as

Asthmacorticosteroiddisease exacerbationlung function testsphenotypeprescription patterns

Identifiers

PMID35557495
PMCPMC9110914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.